| Identification | Back Directory | [Name]
ABT-639 | [CAS]
1235560-28-7 | [Synonyms]
ABT-639
4-Chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide | [Molecular Formula]
C20H20ClF2N3O3S | [MDL Number]
MFCD29924737 | [MOL File]
1235560-28-7.mol | [Molecular Weight]
455.91 |
| Chemical Properties | Back Directory | [Boiling point ]
612.2±65.0 °C(Predicted) | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:9.71(Max Conc. mg/mL);21.3(Max Conc. mM)
DMF:14.0(Max Conc. mg/mL);30.71(Max Conc. mM)
DMF:PBS (pH 7.2) (1:20):0.04(Max Conc. mg/mL);0.09(Max Conc. mM)
Ethanol:0.5(Max Conc. mg/mL);1.1(Max Conc. mM) | [form ]
A solid | [pka]
6.80±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
AGPIHNZOZNKRGT-CYBMUJFWSA-N | [SMILES]
Fc1c(cc(c(c1)Cl)C(=O)N3C[C@@H]4N(CC3)CCC4)[S](=O)(=O)Nc2c(cccc2)F |
| Safety Data | Back Directory | [WGK Germany ]
WGK 3 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral
Skin Irrit. 2 |
| Questions and Answers (Q&A) | Back Directory | [Description]
ABT-639 is a selective T-type calcium channel blocker with efficacy in a wide range of preclinical models of nociceptive and neuropathic pain.ABT-639 produces robust antinociceptive activity in experimental pain models at doses that do not significantly alter psychomotor or hemodynamic function in the rat.
| [References]
Zhang, Q., et al. "Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639."Acs Medicinal Chemistry Letters6.6(2015):150429091057009.
Serra, J, et al. "Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. " Pain 156.11(2015):2175.
http://www.medkoo.com/products/6989
|
| Hazard Information | Back Directory | [Uses]
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. | [in vivo]
ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50=2 μM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 μM). ABT-639 is significantly less active at other Ca2+ channels (e.g. Cav1.2 and Cav2.2) (IC50>30 mM). ABT-639 has high oral bioavailability (%F=73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents. Following oral administration ABT-639 produces dose-dependent antinociception in a rat model of knee joint pain (ED50=2 mg/kg, p.o.). ABT-639 (10-100 mg/kg, p.o.) also increases tactile allodynia thresholds in multiple models of neuropathic pain (e.g. spinal nerve ligation, CCI, and vincristine-induced, and capsaicin secondary hypersensitivity). ABT-639 does not attenuate hyperalgesia in inflammatory pain models induced by complete Freund’s adjuvant or carrageenan. At higher doses (e.g. 100-300 mg/kg) ABT-639 does not significantly alter hemodynamic or psychomotor function. The antinociceptive profile of ABT-639 provides novel insights into the role of peripheral T-type (Cav3.2) channels in chronic pain states[1]. | [IC 50]
T-type calcium channel | [storage]
Store at -20°C |
|
|